Brian Windsor
President & Chief Executive Officer Rein Therapeutics
Dr. Brian Windsor is President and CEO of Aileron Therapeutics, bringing deep expertise in pulmonary drug development, including leadership roles focused on IPF. As former CEO of Lung Therapeutics, he spearheaded the development of inhaled and injectable therapies targeting fibrotic lung diseases. He also served as CSO and Director at TFF Pharmaceuticals, a company spun out from Lung, advancing next-generation pulmonary delivery technologies. With a Ph.D. in Molecular Biology from The University of Texas at Austin, Dr. Windsor has over a decade of executive experience across biotech and pharma, with a focus on translating science into impactful respiratory therapies.
Seminars
Wednesday 20th August 2025
Designing Feasible, Efficient & Effective Clinical Trials in an Era of Expanding Treatment Options
11:30 am
- Explore challenges in patient recruitment, including identifying patients still at risk of disease progression despite SOC treatment
- Optimize inclusion/exclusion criteria and trial design to ensure feasibility while maintaining clinical relevance in a rapidly evolving treatment landscape
- Examine how study design and statistical analyses must adjust for background therapy’s impact on FVC decline, hospitalization rates, and mortality
